Abstract
Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Current Pharmaceutical Design
Title:Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Volume: 19 Issue: 32
Author(s): Miriam Ojeda-Ojeda, Mora Murri, Maria Insenser and Hector F. Escobar-Morreale
Affiliation:
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Abstract: Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Export Options
About this article
Cite this article as:
Ojeda-Ojeda Miriam, Murri Mora, Insenser Maria and Escobar-Morreale F. Hector, Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320012
DOI https://dx.doi.org/10.2174/1381612811319320012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Synthesis and Pancreatic Lipase Inhibitory Activity of Phenacyl Esters of N-Aroyl Amino Acids
Current Enzyme Inhibition Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Current Pharmaceutical Design Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry Measuring the Burden of Disease in the United Arab Emirates, 1990 – 2019: A Road to Future
New Emirates Medical Journal The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology Utility of Intrapartum Transabdominal Ultrasound for the Correct Placement of Vacuum during Assisted Delivery
Current Women`s Health Reviews Preface
Micro and Nanosystems Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets